KR101766502B1 - 인돌 화합물 및 그의 의약 용도 - Google Patents
인돌 화합물 및 그의 의약 용도 Download PDFInfo
- Publication number
- KR101766502B1 KR101766502B1 KR1020127016311A KR20127016311A KR101766502B1 KR 101766502 B1 KR101766502 B1 KR 101766502B1 KR 1020127016311 A KR1020127016311 A KR 1020127016311A KR 20127016311 A KR20127016311 A KR 20127016311A KR 101766502 B1 KR101766502 B1 KR 101766502B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- substituted
- compound
- alkoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FAPOYQXIBRBNJW-UHFFFAOYSA-O CC(C)(CC1)CC([NH3+])=C1C(c1cc(ccc(N(C)C(C)=O)c2)c2[nH]1)=N Chemical compound CC(C)(CC1)CC([NH3+])=C1C(c1cc(ccc(N(C)C(C)=O)c2)c2[nH]1)=N FAPOYQXIBRBNJW-UHFFFAOYSA-O 0.000 description 1
- CKGURMJZTVPJFU-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3NC)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3NC)n[nH]2 CKGURMJZTVPJFU-UHFFFAOYSA-N 0.000 description 1
- UESJEBGRGGURRJ-YSGASBTCSA-N CC(C)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3/N=C\C)n[n]2COCC[Si](C)(C)C Chemical compound CC(C)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3/N=C\C)n[n]2COCC[Si](C)(C)C UESJEBGRGGURRJ-YSGASBTCSA-N 0.000 description 1
- 0 CC(C)(CC1)Cc2c1c(-c1cc(ccc(N(C)C(C)=O)c3)c3[n]1COCC*)n[n]2COCC[Si](C)(C)C Chemical compound CC(C)(CC1)Cc2c1c(-c1cc(ccc(N(C)C(C)=O)c3)c3[n]1COCC*)n[n]2COCC[Si](C)(C)C 0.000 description 1
- VLSUABJDLLMXJS-UHFFFAOYSA-N CC(CO)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[nH]2 Chemical compound CC(CO)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[nH]2 VLSUABJDLLMXJS-UHFFFAOYSA-N 0.000 description 1
- NIBMSVVMFOAWIZ-UHFFFAOYSA-N CC(CO)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[n]2COCC[Si](C)(C)C Chemical compound CC(CO)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[n]2COCC[Si](C)(C)C NIBMSVVMFOAWIZ-UHFFFAOYSA-N 0.000 description 1
- NLZYZSHOSOLTAA-UHFFFAOYSA-N CC(CO)(CCC1)CC11OCCO1 Chemical compound CC(CO)(CCC1)CC11OCCO1 NLZYZSHOSOLTAA-UHFFFAOYSA-N 0.000 description 1
- XJGFNJZYOIZNEW-UHFFFAOYSA-N CC(CO)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O Chemical compound CC(CO)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O XJGFNJZYOIZNEW-UHFFFAOYSA-N 0.000 description 1
- RTQSZFGSJOYNTH-UHFFFAOYSA-N CC(COCc1ccccc1)(CCC1)CC11OCCO1 Chemical compound CC(COCc1ccccc1)(CCC1)CC11OCCO1 RTQSZFGSJOYNTH-UHFFFAOYSA-N 0.000 description 1
- XCOPYDBCXYNXRE-UHFFFAOYSA-N CC(CO[Si](C(C)(C)C)(c1ccccc1)c1ccccc1)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O Chemical compound CC(CO[Si](C(C)(C)C)(c1ccccc1)c1ccccc1)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O XCOPYDBCXYNXRE-UHFFFAOYSA-N 0.000 description 1
- ZZZXGCPVQQOASC-INIZCTEOSA-N C[C@@H](C(N(C)c1ccc(cc(-c2n[nH]c3c2CCC(C)(C)C3)[nH]2)c2c1)=O)N1CCOCC1 Chemical compound C[C@@H](C(N(C)c1ccc(cc(-c2n[nH]c3c2CCC(C)(C)C3)[nH]2)c2c1)=O)N1CCOCC1 ZZZXGCPVQQOASC-INIZCTEOSA-N 0.000 description 1
- WEJKUVSYIGOBAR-LURJTMIESA-N C[C@@H](C(O)=O)N1CCOCC1 Chemical compound C[C@@H](C(O)=O)N1CCOCC1 WEJKUVSYIGOBAR-LURJTMIESA-N 0.000 description 1
- CDSJDFVITCHACO-UHFFFAOYSA-N O=C(CN(CCOC1)C1=O)OCc1ccccc1 Chemical compound O=C(CN(CCOC1)C1=O)OCc1ccccc1 CDSJDFVITCHACO-UHFFFAOYSA-N 0.000 description 1
- SZUPCAZDKKJKEX-UHFFFAOYSA-N OC(CN(CCOC1)C1=O)=O Chemical compound OC(CN(CCOC1)C1=O)=O SZUPCAZDKKJKEX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2009-268040 | 2009-11-25 | ||
| JP2009268040 | 2009-11-25 | ||
| PCT/JP2010/070988 WO2011065402A1 (ja) | 2009-11-25 | 2010-11-25 | インドール化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120096540A KR20120096540A (ko) | 2012-08-30 |
| KR101766502B1 true KR101766502B1 (ko) | 2017-08-08 |
Family
ID=44066507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127016311A Active KR101766502B1 (ko) | 2009-11-25 | 2010-11-25 | 인돌 화합물 및 그의 의약 용도 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US8299070B2 (enExample) |
| EP (3) | EP3766877A1 (enExample) |
| JP (6) | JP5734628B2 (enExample) |
| KR (1) | KR101766502B1 (enExample) |
| CN (1) | CN102712624B (enExample) |
| AR (1) | AR079164A1 (enExample) |
| AU (1) | AU2010323579C1 (enExample) |
| BR (1) | BR112012012529B1 (enExample) |
| CA (1) | CA2781660C (enExample) |
| CL (1) | CL2012001328A1 (enExample) |
| CO (1) | CO6541645A2 (enExample) |
| CY (1) | CY1117559T1 (enExample) |
| DK (1) | DK2505586T3 (enExample) |
| ES (1) | ES2572935T3 (enExample) |
| HR (1) | HRP20160579T1 (enExample) |
| HU (1) | HUE028016T2 (enExample) |
| IL (1) | IL220009A (enExample) |
| ME (1) | ME02447B (enExample) |
| MX (1) | MX2012006017A (enExample) |
| MY (1) | MY161095A (enExample) |
| NZ (1) | NZ600840A (enExample) |
| PE (1) | PE20121358A1 (enExample) |
| PH (1) | PH12012501021A1 (enExample) |
| PL (1) | PL2505586T3 (enExample) |
| PT (1) | PT2505586E (enExample) |
| RS (1) | RS54910B1 (enExample) |
| RU (1) | RU2556216C2 (enExample) |
| SI (1) | SI2505586T1 (enExample) |
| SM (1) | SMT201600258B (enExample) |
| TW (1) | TWI491591B (enExample) |
| WO (1) | WO2011065402A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| PE20151604A1 (es) * | 2012-11-02 | 2015-11-04 | Pharmacyclics Llc | Terapia adyuvante con inhibidores de quinasa de la familia tec |
| CN103804364A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| CN103800328A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804361A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800337A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804291A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800340A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
| CN103804351A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804302A (zh) * | 2012-11-14 | 2014-05-21 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103804363A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804272A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| TW201625605A (zh) * | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| US20170253577A1 (en) | 2014-07-04 | 2017-09-07 | Japan Tobacco Inc. | Method for producing indole compound |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| CN104356086A (zh) * | 2014-11-28 | 2015-02-18 | 湖南科技大学 | 一种适于工业生产3-吗啉酮的制备方法 |
| CA3100675A1 (en) * | 2018-05-25 | 2019-11-28 | Japan Tobacco Inc. | Method of treating pain or interstitial cystitis using indole compound |
| JP7322007B2 (ja) * | 2018-05-25 | 2023-08-07 | 日本たばこ産業株式会社 | インドール化合物を含むネフローゼ症候群の治療又は予防剤 |
| WO2019225740A1 (ja) | 2018-05-25 | 2019-11-28 | 日本たばこ産業株式会社 | インドール化合物を含む多発性硬化症の治療又は予防剤 |
| CN115087655A (zh) | 2019-12-20 | 2022-09-20 | 辉瑞公司 | 苯并咪唑衍生物 |
| KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
| JP2023552863A (ja) * | 2020-12-15 | 2023-12-19 | ファイザー・インク | ベンゾイミダゾール誘導体および皮膚疾患の処置のためのｉｔｋの阻害剤としてのそれらの使用 |
| EP4263538A1 (en) * | 2020-12-15 | 2023-10-25 | Pfizer Inc. | Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
| CN117693502A (zh) * | 2021-05-03 | 2024-03-12 | 纽力克斯治疗公司 | 用于抑制或降解itk的化合物、包含其的组合物、其制备方法及其使用方法 |
| TW202315618A (zh) * | 2021-06-11 | 2023-04-16 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物 |
| EP4419520A2 (en) * | 2021-10-19 | 2024-08-28 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway |
| EP4695241A1 (en) * | 2023-04-13 | 2026-02-18 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolone derivatives, compositions and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2008135785A1 (en) * | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b] pyridin-5-amine derivatives and their use for the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US953411A (en) * | 1908-09-02 | 1910-03-29 | Erastus De Moulin | Trick weight-lifting machine. |
| MXPA04003954A (es) * | 2001-10-26 | 2004-11-29 | Aventis Pharma Inc | Bencimidazoles. |
| NZ555911A (en) * | 2002-01-07 | 2008-07-31 | Eisai R&D Man Co Ltd | Deazapurines and uses thereof |
| FR2854159B1 (fr) * | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| DE602004027288D1 (en) * | 2003-09-08 | 2010-07-01 | Aventis Pharma Inc | Thienopyrazole |
| AU2006237920A1 (en) * | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
| WO2007076228A2 (en) | 2005-12-20 | 2007-07-05 | Boehringer Ingelheim International Gmbh | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders |
| GB0602178D0 (en) | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| CN101437519A (zh) * | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| US8604031B2 (en) * | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| JPWO2008047831A1 (ja) * | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| WO2008058402A1 (en) | 2006-11-17 | 2008-05-22 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| JP2009268040A (ja) | 2008-04-23 | 2009-11-12 | Teruhiko Daiho | ループアンテナ装置 |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
-
2010
- 2010-11-24 US US12/954,438 patent/US8299070B2/en active Active
- 2010-11-25 RU RU2012126129/04A patent/RU2556216C2/ru active
- 2010-11-25 TW TW099140715A patent/TWI491591B/zh active
- 2010-11-25 EP EP20189306.2A patent/EP3766877A1/en not_active Withdrawn
- 2010-11-25 HU HUE10833248A patent/HUE028016T2/en unknown
- 2010-11-25 ME MEP-2016-107A patent/ME02447B/me unknown
- 2010-11-25 CN CN201080062299.3A patent/CN102712624B/zh active Active
- 2010-11-25 MY MYPI2012002292A patent/MY161095A/en unknown
- 2010-11-25 BR BR112012012529-0A patent/BR112012012529B1/pt active IP Right Grant
- 2010-11-25 PH PH1/2012/501021A patent/PH12012501021A1/en unknown
- 2010-11-25 SI SI201031188A patent/SI2505586T1/sl unknown
- 2010-11-25 JP JP2010262058A patent/JP5734628B2/ja active Active
- 2010-11-25 HR HRP20160579TT patent/HRP20160579T1/hr unknown
- 2010-11-25 NZ NZ600840A patent/NZ600840A/en unknown
- 2010-11-25 AU AU2010323579A patent/AU2010323579C1/en active Active
- 2010-11-25 EP EP10833248.7A patent/EP2505586B1/en active Active
- 2010-11-25 RS RS20160385A patent/RS54910B1/sr unknown
- 2010-11-25 DK DK10833248.7T patent/DK2505586T3/en active
- 2010-11-25 ES ES10833248.7T patent/ES2572935T3/es active Active
- 2010-11-25 PL PL10833248.7T patent/PL2505586T3/pl unknown
- 2010-11-25 WO PCT/JP2010/070988 patent/WO2011065402A1/ja not_active Ceased
- 2010-11-25 MX MX2012006017A patent/MX2012006017A/es active IP Right Grant
- 2010-11-25 KR KR1020127016311A patent/KR101766502B1/ko active Active
- 2010-11-25 EP EP16158053.5A patent/EP3059234A1/en not_active Withdrawn
- 2010-11-25 PT PT108332487T patent/PT2505586E/pt unknown
- 2010-11-25 CA CA2781660A patent/CA2781660C/en active Active
- 2010-11-25 AR ARP100104362A patent/AR079164A1/es active IP Right Grant
- 2010-11-25 PE PE2012000713A patent/PE20121358A1/es active IP Right Grant
-
2012
- 2012-05-23 CL CL2012001328A patent/CL2012001328A1/es unknown
- 2012-05-24 IL IL220009A patent/IL220009A/en active IP Right Grant
- 2012-06-22 CO CO12105036A patent/CO6541645A2/es active IP Right Grant
- 2012-09-26 US US13/627,047 patent/US20130116240A1/en not_active Abandoned
-
2015
- 2015-04-15 JP JP2015083457A patent/JP2015172051A/ja not_active Ceased
-
2016
- 2016-05-26 CY CY20161100462T patent/CY1117559T1/el unknown
- 2016-08-03 SM SM201600258T patent/SMT201600258B/it unknown
- 2016-10-20 JP JP2016205949A patent/JP2017039761A/ja not_active Ceased
- 2016-10-28 US US15/337,583 patent/US20170267662A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,250 patent/US20180362506A1/en not_active Abandoned
- 2018-06-13 JP JP2018112445A patent/JP2018158935A/ja active Pending
-
2019
- 2019-09-19 US US16/575,724 patent/US20200255408A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020017065A patent/JP2020079276A/ja not_active Ceased
- 2020-09-23 US US17/029,642 patent/US20210284627A1/en not_active Abandoned
-
2021
- 2021-03-03 JP JP2021033138A patent/JP2021091718A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2008135785A1 (en) * | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b] pyridin-5-amine derivatives and their use for the treatment of cancer |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101766502B1 (ko) | 인돌 화합물 및 그의 의약 용도 | |
| KR20060087598A (ko) | Ｎ-[헤테로아릴(피페리딘-2-일)메틸]벤즈아미드의 유도체,그의 제조 방법 및 치료법에서의 그의 용도 | |
| JP6250667B2 (ja) | 新しい抗菌化合物 | |
| CA2842526C (en) | Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
| KR20050121681A (ko) | 면역조절 헤테로고리 화합물 | |
| WO2017140269A1 (zh) | 一类取代的氨基六元氮杂环类化合物及其制备和用途 | |
| JP6250668B2 (ja) | 新しい抗菌化合物 | |
| HK1174025B (en) | Indole compound and pharmaceutical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20120622 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20151109 Comment text: Request for Examination of Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161031 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170523 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20170802 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20170802 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20200630 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210629 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220615 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240619 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250616 Start annual number: 9 End annual number: 9 |